Sexual Health Β· NeuralTier 1 β Strong clinical evidence (RCTs)
PT-141
Bremelanotide Β· Vyleesi
FDA-approved melanocortin agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Also used off-label for erectile dysfunction in men, acting centrally rather than on blood vessels.
π SC injection / Intranasalπ§ Refrigerate at 2β8Β°C; after removal from fridge use within 30 days
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Activates MC3R and MC4R receptors in the hypothalamus and limbic system, directly enhancing sexual arousal circuits independent of nitric oxide pathways (unlike PDE5 inhibitors).
Clinical Applications
- βHSDD in premenopausal women (FDA approved)
- βErectile dysfunction (off-label, especially psychogenic or centrally-mediated)
- βLow libido in both sexes
- βSexual dysfunction from antidepressant use
Dosing Protocol
Recommended Dosing
SC injection (Vyleesi). 1.75 mg SC, 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours and 8 doses per month. Can also use intranasal formulation (compounded).Safety & Contraindications
Possible Side Effects
- β Nausea (most common β up to 40% in trials)
- β Flushing
- β Headache
- β Transient hypotension
- β Hyperpigmentation with frequent use
- β Injection site reactions
Contraindications
- βCardiovascular disease (transient BP elevation)
- βUncontrolled hypertension
- βPregnancy
- βUse with naltrexone or other opioid antagonists β interaction risk
Combinations & Synergies
π Kisspeptincentral sexual function synergy
π Avoid with Melanotan II (overlapping melanocortin activation β increased side effects)